Kornimate/medical-research-clean huggingface dataset:
prevalence of internet addiction and it's effects on psychological well-being of adults in hong kong

Conditions: Internet Addiction

Summary: the goal of this quantitative study is to learn about the the prevalence of internet addiction and its effects on psychological well-being of adults in hong kong. the main question it aims to answer is: • what is the prevalence of internet addiction and its effects on psychological well-being of adults in hong kong participants will be invited to complete a set of questionnaire that includes assessment on their level of internet use, depression, anxiety, sleep quality, qol together with basic demographic data in the current situation of covid with popularity of metaverse..

internet addiction (ia) appeared to become serious issues since the emergence of internet over the decades. the definition of internet penetration rate (ipr) is the percentage of the entire population who has internet usage. as of july 2022, denmark, the uae, and ireland had the highest ipr, all recording 99% of their population accessing the internet. while in hong kong, it has reached 93.6%, not far from the first in asia - south korea (98%). the widespread use has shown the popularity of internet is skyrocketing through the years. despite there are several studies conducted on ia from the west, the results might not be not applicable in adults in hong kong due to various reasons such as policies against covid and cultural difference as lifestyle, living and social environment, family relationship style. those might have potential influence on the engagement in physical and social activities and involvement in internet. in addition to the emergence of metaverse, situations, policies and people's attitude towards covid might have changed drastically and affect the prevalence of ia in hong kong adult. to conclude, the effect of covid and metaverse on the prevalence of ia in adults in hong kong and the mechanisms/reasons behind is unclear. in the present study, the investigators aim to investigate the prevalence and effects of ia on the psychosocial well-being among adults in hong kong by measuring the level of internet use, depression, anxiety, sleep quality, qol together with basic demographic data in the current situation of covid with popularity of metaverse.

Eligibility criteria:
inclusion criteria: * adults aged 18-40 * resided in hong kong * can speak cantonese and write chinese exclusion criteria: * self-reported to have identified cognitive problems and communication problems

Keywords: internet addiction quality of life young adults
identification of risk factors parkinson's disease by convergence strategy

Conditions: Parkinson Disease

Summary: using this convergence approach from a limited group of subjects with non-diseased controls, patients with parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to parkinson disease. these genes will then be studied using a case-control genetic epidemiology approach. the risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in parkinson's subjects and healthy controls in the second group of subjects. the specificity of the genetic associations found will be evaluated in subjects with parkinson's disease.


Eligibility criteria:
inclusion criteria: * inclusion criteria for parkinson's patients and "related diseases" controls: * parkinsonian patients meeting the gelb criteria * patients with other neurodegenerative disease (such as other parkinson syndrome or synucleopathies) meeting the criteria set out in appendix 2 (lewy bodies dementia, parkinson's disease with dementia, multisystem atrophy, progressive supranuclear paralysis) , amyotrophic lateral sclerosis, restless legs syndrome, alzheimer's disease). * woman of childbearing age having an effective means of contraception. * informed consent signed by the subject or his legal representative. * for demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative. criteria for inclusion of non-ill controls: * absence of rest trembling, bradykinesia and stiffness * mmse (mini mental state examination) greater than 25 * woman of childbearing age having an effective means of contraception. * subject having signed the informed consent. * no family history of neurodegenerative disease that started before age 70. these controls will not present any parkinsonian signs during the clinical evaluation. they may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the mmse test. exclusion criteria: * criteria for non-inclusion of patients: * clinical criteria for exclusion of the diseases described * participation in another therapeutic trial or in the exclusion period of a previous clinical trial. criteria for non-inclusion of non-ill controls: * functional discomfort in daily life of unknown cause * mmse less than 25 * participation in another therapeutic trial or in the exclusion period of a previous clinical trial.
involvement of translation initiation factors in the immune response in the elderly

Conditions: Elderly Patient; Infection

Summary: the investigators propose that the translation initiation factors eif4e and eif4gi may be involved in resolution of acute inflammation (regardless of age). furthermore, the investigators suggest that differences in translation initiation factors state of activation may contribute to inflammation. finally, the investigators hypothesize that differences in translation initiation factors state of activation may underlie the immune compromised state of the very elderly affording additional explanation for the heightened morbidity from infection in this group. in the current study the investigators aim to test these hypotheses by measuring the levels of eif4e and eif4g, their regulators, and targets in elderly (65-84yrs) and very elderly (85yrs\<) patients hospitalized at meir hospital for acute infection and after their recovery (detailed in study design).


Eligibility criteria:
inclusion criteria: * elderly patients (65\<) * hospitalized for acute infection (fever 38c\<, leukocytosis) exclusion criteria: * patients with dementia who can not sign informed consent of institutional helsinki committee * patient with active cancer with active chemotherapy treatment

Keywords: elderly patients acute infection translation initiation factors eif4e eif4g
study the feasibility of permanent use of incontrol for the treatment of type 1 diabetes

Conditions: Type 1 Diabetes

Summary: a new version of the dias artificial pancreas (ap) system has been developed in view of wide scale outpatient trials. denominated as incontrol , it includes improved user interface and communication modules while closed-loop algorithms remain similar. during this pilot study, the investigators will evaluate this new version of ap for a two-week period during which the patients will use it for closed-loop insulin delivery 24/7 the main goal is train the clinical team with the new system and collect patient opinions on system acceptance from questionnaires. if this trial is conclusive, a randomized 6-month multicentre study including 240 patients will be initiated. a total of 5 patients will be included in this training study over a 4-week period.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus since more than one year, treated by insulin since at least one year * treatment by insulin pump since at least 6 months * glycated hemoglobin (hba1c) below 10.5% at inclusion visit * for women of child bearing age, no current pregnancy and use of an efficient contraception during the whole research participation * agreement on no use of drugs or products used for reduction of blood glucose levels, such as metformin or glp1 analogs, except if this therapy has been used for at least 3 months before study start * agreement on stopping closed-loop insulin delivery after acetaminophen use and 4 following hours * agreement on suspending use of patient cgm device during the study period while study cgm will be used * access to the internet and a mobile phone network at home * agreement on following study procedures * affiliation to the french social security system or a similar healthcare coverage system * mandatory written informed consent exclusion criteria: * need for chronic use of acetaminophen * start of use of drugs or products used for reduction of blood glucose levels, such as metformin or glp1 analogs during the 3 months before inclusion * hemophilia or other coagulation disorders * psychological and/or cognitive troubles which may impair the appropriate following of study procedures * diabetic ketoacidosis during the last 6 months * acute cardiovascular event during the last 12 months * severe hypoglycaemia with convulsions or loss of conscience during the last 12 months * use of a therapy with significant impact on glucose metabolism * cystic fibrosis * lack of nearby third-party assistance availability in case of troubles * malignant disease, except if considered as cured since at least 10 years * impaired kidney function (serum creatinin \> 150 umol/l) * impaired liver status (alat or asat \> 2-times upper normal limit) * active gastroparesis * acute adrenocortical event * alcohol or narcotics abuse

Keywords: type 1 diabetes artificial pancreas closed-loop insulin infusion
improvement of the nutritional status regarding nicotinamide (vitamin b3) and the disease course of covid-19

Conditions: COVID-19

Summary: based on the literature, it seems likely that a nutritional intervention with nicotinamide (a form of vitamin b3) can support the therapy of sars-cov-2 infection (covid-19). a pilot phase of the covit trial showed an effect of nicotinamide on the time to complete resolution of covid-19 symptoms. in addition, diarrhoea is a common symptom of covid-19. therefore, in a second part of the study, 420 symptomatic patients each with confirmed sars-cov-2 infection are to take 1,000 mg nicotinamide (500 mg conventional nicotinamide and 500 mg nicotinamide released in a controlled manner in the intestine) or corresponding placebos per day in a blinded fashion for 4 weeks. the primary endpoint of the trial is the occurrence of individual covid-19 symptoms over time (primary analysis time point: week 2). secondary endpoints focus on the severity of covid-19 symptoms, the post-covid-19 syndrome (pcs), anti-sars-cov-2 antibody levels, and the time to resolution of individual or all symptoms. exploratory endpoints include the who clinical scale for covid-19, development of severe covid-19, fatigue, quality of life and biomarkers. patients are approached after positive testing and give their informed consent online. after randomised distribution of the trial supplements, patients are interviewed by telephone about their disease course at baseline (week 0), week 2, week 4, week 6 and after 6 months. stool samples are collected from up to 400 patients at the same timepoints. in addition to blood count and standard blood profile, various inflammatory markers and the metabolome, in particular tryptophan metabolism, are examined in the blood of up to 20 selected patients. in these patients, the viral strain is determined by sequencing from nasopharyngeal swabs. in selected patients, short-term pharmacokinetics of nicotinamide, nicotinic acid and nicotinuric acid as well as of metabolites of nicotinamide and tryptophan are investigated. in the stool, changes in the microbiome (in 100-300 patients) as well as metagenome and metabolome (in a subgroup) will be analysed. the study is expected to produce rapid results on whether nicotinamide supplementation can alleviate the disease course of covid-19. moreover, a follow-up interview, a smell test, a cognitive test and anti-sars-cov-2 antibody levels after at least 6 months will be used to investigate whether the supplementation has any influence on pcs as well as the immune reaction against sars-cov-2.


Eligibility criteria:
inclusion criteria: * the patient is of age (at least 18 years). * sars-cov-2 infection confirmed by laboratory findings; the positive test must not date back more than 7 days. * relevant infection symptoms, e.g. in the respiratory or gastrointestinal tract. * the patient has been able to give written consent via a website before any trial procedure is performed and can comply with the trial-dependent prerequisites and requirements. exclusion criteria: * current participation in another trial. * pregnancy or breastfeeding. * vaccination against sars-cov-2.
a study of the absorption of gt267-004 in patients with clostridium difficile-associated diarrhea

Conditions: Pseudomembranous Colitis; Clostridium Difficile Diarrhea; Antibiotic-Associated Diarrhea

Summary: approximately 24 patients will be entered into this study taking place in canada. the aim of this study is to determine if an investigational drug is absorbed (taken up) in patients with c. difficile-associated diarrhea (cdad). the investigational drug will be given in addition to current standard antibiotic treatment so that all patients will receive active medication. all study related care is provided including doctor visits, physical exams, laboratory tests, and study medication. the total length of participation is approximately 7 days.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * the presence of cdad at the time of enrollment with no other likely etiology for the diarrhea exclusion criteria: * \> 72 hours of treatment with metronidazole, vancomycin, or other antibacterial therapy specifically targeting the current acute episode of cdad * patient not considered sufficiently stable clinically to complete the study period

Keywords: clostridium difficile-associated diarrhea c. difficile cdad clostridium difficile clostridium difficile disease clostridium enterocolitis antibiotic-associated colitis infectious diarrhea
multicenter trial treatment of philadelphia chromosome negative b-cell acute lymphoblastic leukemia of young adults

Conditions: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to prospectively validate the new risk model, based on minimal residual disease (mrd) response level and oncogenetic status by comparing historical results of graall-2005 with those of graall-2014 in an identical population of patients (philadelphia chromosome negative, b lineage all, aged 18 to 59 years old).


Eligibility criteria:
inclusion criteria: 1. whose blood and bone marrow explorations have been completed before the steroids prephase 2. aged 18 to 59 years old with not previously treated (including intrathecal injection) b-lineage-all newly diagnosed according to the who 2008 definition with ≥ 20% bone marrow blasts 3. whose karyotype shows no t(9;22) and/or the absence in molecular biology of breakpoint cluster region-abelson (bcr-abl) 4. with eastern cooperative oncology group (ecog) performance status ≤3 5. with or without central nervous system (cns) or testis involvement 6. without other evolving cancer (except basal cell carcinoma of the skin or "in situ" carcinoma of the cervix) or its radiotherapy or chemotherapy treatment should be finished at least since 6 months 7. having signed a written informed consent 8. with efficient contraception for women of childbearing age (excluding estrogens and iud) 9. with health insurance coverage 10. who have received or being receiving the steroid prephase exclusion criteria: 1. with lymphoblastic lymphoma and bone marrow blasts \< 20%, burkitt-type all, or with antecedents of chronic myeloid leukemia (cml) or other myeloproliferative neoplasm 2. with contra-indication to anthracyclines or any other general or visceral contra-indication to intensive therapy except if considered related to the all: * aspartate transaminase (ast) and/or alanine transaminase (alt) \> 5 x upper limit of normal range (uln) * total bilirubin ≥ 2.5 x upper limit of normal range (uln) * creatinine \>1.5x upper limit of normal range (uln) or creatinine clearance \<50 ml/mn 3. myocardial infarction within 6 months prior to inclusion in the trial, cardiomyopathy (nyha grade iii or iv), left ventricle ejection fraction (lvef) \< 50% and or shortening fraction \< 30%, 4. active severe infection or known seropositivity for hiv or human t cell leukemia/lymphoma virus type 1 (htlv1) or active hepatitis b or c 5. pregnant (beta-human chorionic gonadotropin positive) or nursing woman 6. not able to bear with the procedures or the frequency of visits planned in the trial 7. unable to consent, under tutelage or curators, or judiciary safeguard.
management of pilon fractures with versus without fibula fixation

Conditions: Pilon Fracture

Summary: management of pilon fractures with versus without fibula fixation

comparing results with or without fibular fixation in : * rate of bone union . * functional return ( clinical outcomes) * alignment of lower limb.

Eligibility criteria:
inclusion criteria: * patients with metaphyseal non rotational pilon or distal tibia : age ( 18 _ 65 ) * no skin troubles * no infections * non-dibetic patients. exclusion criteria: * patients who will not complete their follow up. * skin troubles * infections
quality of life after wide surgical excision in patients with hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa; Wide Excision

Summary: patients undergoing wide surgical excision of their hidradenitis suppurativa areas are asked by telephone about their quality of life by standard questionnaires (whoqol-bref, dlqi, skindex, mhf, flqa-d) and their sexual function (fsfi, iief).


Eligibility criteria:
inclusion criteria: * hidradenitis suppurativa that was wide excised in 2013 in fachklinik hornheide * agreed to retrospective analysis and questionnaires exclusion criteria: * non-compliance

Keywords: hidradenitis suppurativa wide excision quality of life sexual function
myomectomy operation and fundus incision, energy modalities and methods of extraction

Conditions: Myoma;Uterus; Surgery

Summary: myomectomy operation due to myoma uteri is an operation that can cause serious blood loss. for some anatomical reasons, fundal myomas were removed, while a group of investigators recommended the initiation of a longitudinal incision and some surgeons preferred a transverse incision. the authors aim to show some surgical differences, intraoperative blood loss, and difficulties and ease of removal of myoma in patients with these approaches without consensus. it is also noted that the incision made with the same energy modality is recorded; the effect of energy modality on blood loss and surgical comfort will be examined. different approaches are used for laparoscopic surgical operations in order to remove myoma from the abdomen. it can be removed from the vagina by colpotomy and can also be minimized in the abdomen by a morselator. in particular, patients with vaginal myoma removed, such as complaints of postoperative dyspareunia will be followed. in this way, the investigators aim to evaluate the methods which have not yet gained clarity in the literature or have not proven superiority to each other.


Eligibility criteria:
inclusion criteria: - patients operated with the diagnosis of myoma uteri exclusion criteria: * cardiopulmonary diseases such as cardiac insufficiency, myocardial infarction, unstable angina, acute or new vascular thrombosis, asthma or pulmonary obstructive disease; * patients with long-term trendelenburg contraindications; * previous pelvic or abdominal radiation therapy; or those with inadequate bone marrow, kidney and hepatic function; * gynecological malignancies. * those who received preoperative medication due to myoma uteri

Keywords: myomectomy fundus incision energy modalities methods of extraction
efficacy and safety of naftopidil in patient with neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia

Conditions: Neurogenic Lower Urinary Tract Dysfunction

Summary: this study is designed to evaluate efficacy and safety of naftopidil in patient with neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: 1. male or female aged 20 years old and above (upper limit of age: 80 years old) 2. patients diagnosed as neurogenic bladder due to cerebrovascular accident, parkinson disease, spinal cord lesion, diabetic neuropathy etc) 3. a+b 1. ipss ≥ 12 and qol ≥ 3 2. maximum flow rate \<15 ml/s (voiding volume) ≥ 120ml) 4. ability and willingness to correctly complete the micturition diary and questionnaire 5. capable of understanding and having signed the informed consent form after full discussion of the research nature of the treatment and its risks and benefits exclusion criteria: 1. in male aged 50 years old and above, bladder outlet obstruction (bladder outlet obstruction index(booi) ≥40) 2. in female, pelvic organ prolapse ics stage; pop-q stage ≥ 2 3. in female, the history of anti-incontinence operation. 4. patients with cancer of any type including cancer of the prostate or bladder 5. patients with urethral stricture or bladder neck contracture

Keywords: naftopidil safety
the effect of prometheus (r) liver support dialysis on cerebral metabolism in acute liver failure

Conditions: Acute Liver Failure; Hepatic Encephalopathy; Intracranial Hypertension

Summary: the main objective of this study is to investigate the effect of prometheus liver support dialysis on intracranial pressure, cerebral metabolism and circulation in patients with acute liver failure.

acute liver failure (alf) is a highly mortal medical condition often complicated by multiorgan failure. apart from severe coagulopathy alf is characterized by onset of hepatic encephalopathy and in many cases intracranial hypertension (ich) with the risk of cerebral incarceration. the pathogenesis behind ich is incompletely understood and the therapeutic options are limited. prometheus (r) liver support dialysis offers a system that apart from regular high-flux hemodialysis to a certain extent is able of removing albumin-bound substances from the patient - a feature that theoretically could benefit patients with alf. in this study we intend to investigate the effect of 6-8 hours of prometheus (r) liver support dialysis on cerebral metabolism, ich and cerebral bloodflow (cbf) in patients with alf. the study is designed as a open, prospective and randomized study, where a control-group treated with 6-8 hours of continuously veno-venous hemodiafiltration (cvvhdf) and standard medical treatment (smt) is compared to the intervention group treated with prometheus (r) liver support dialysis and smt. the study is designed as a cross-over study so that included patients will be treated in both groups in a randomized order. the primary end-points are treatment effect on intracranial pressure, cbf and cerebral oxidative metabolism (lactate/pyruvate-ratio). we use a intracranial monitoring system from integra/camino (r) (united states) in combination with cma microdialysis system and bedside analyzer (cma-600) (stockholm, sweden).

Eligibility criteria:
inclusion criteria: * acute liver failure * and grade ii-iv encephalopathy * and persistent raised arterial ammonia-concentration above 150 micromol/l * and informed consent from closest relative and general practitioner exclusion criteria: * withdrawal of informed consent * severe untreated infection * active bleeding within 48 hours * suspicion of malignant liver disease * severe heart insufficiency or middle artery pressure below 60 mmhg in spite of vasoactive therapy * pregnant or lactating women * disseminated intravascular coagulation * clinical suspicion of cerebral damage